AOD-9604 2mg (10 vials/kit): Lipolytic C-Terminal hGH Fragment for Metabolic Research

AOD-9604 (Advanced Obesity Drug 9604) is a synthetic modified peptide fragment corresponding to the C-terminal amino acid region of human growth hormone ($\text{hGH}_{177-191}$) with an added N-terminal tyrosine residue ($\text{Tyr-hGH}_{177-191}$). Exhibiting the chemical sequence $\text{Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe}$, AOD-9604 retains the lipolytic (fat-burning) domain of intact growth hormone while lacking the diabetogenic and growth-promoting properties mediated by systemic insulin-like growth factor 1 ($\text{IGF-1}$). Sourcing AOD-9604 2mg (10 vials/kit) provides metabolic researchers, endocrinologists, and preclinical research laboratories with a high-purity analytical reagent engineered to isolate lipid oxidation pathways and cell-surface beta-3 adrenergic signaling.

In physiological and metabolic research, AOD-9604 is distinguished by its selective lipolytic mechanism. It stimulates beta-3 adrenergic receptor pathways on adipocytes, accelerating the enzymatic breakdown of stored triglycerides into free fatty acids ($\text{FFAs}$) and glycerol (lipolysis) while simultaneously suppressing lipogenesis (the formation of new fat stores). Crucially, because AOD-9604 lacks the N-terminal functional domains of native growth hormone, it does not induce insulin resistance, alter fasting blood glucose levels, or stimulate systemic cell proliferation, making it an ideal candidate for targeted metabolic assays.

Maintaining batch stability and structural integrity is essential for quantitative lipid oxidation and receptor-binding bioassays. The AOD-9604 2mg (10 vials/kit) configuration supplies a total yield of 20mg active peptide material (2mg per vial) distributed across ten individual USP Type I borosilicate glass vials. Freeze-dried under sterile vacuum conditions, each vial contains a uniform, highly stable lyophilized powder cake. This multi-vial kit structure enables laboratory personnel to reconstitute only the working volume needed for active experimental runs, keeping remaining kit stock preserved in sub-zero stasis to eliminate structural loss caused by repeated freeze-thaw cycles.

Lipolytic Pathways, Metabolic Regulation, and Technical Profile

The primary scientific value of AOD-9604 2mg (10 vials/kit) stems from its targeted action on lipid metabolism without cross-reacting with systemic growth or glycemic pathways:

• Selective Lipolysis Activation: Stimulates beta-3 adrenergic receptors on white adipose tissue, upregulating hormone-sensitive lipase ($\text{HSL}$) activity to drive triglyceride breakdown.

• Inhibition of Lipogenesis: Prevents the conversion of non-fat food substrates into body fat by downregulating key lipogenic enzymes within mature adipocytes.

• Non-Diabetogenic Profile: Operates independently of insulin receptors, demonstrating zero adverse impact on plasma glucose kinetics or insulin sensitivity in preclinical models.

• Absence of IGF-1 Induction: Fails to bind classical growth hormone receptors or stimulate hepatic $\text{IGF-1}$ release, preventing somatic tissue proliferation or organomegaly.

• Disulfide Bridge Stability: Retains an internal disulfide bond ($\text{Cys7-Cys14}$) critical for biological conformation and enzymatic stability in serum assays.

• Ultra-High Chemical Purity ($\ge$99.0%): Manufactured via automated Solid-Phase Peptide Synthesis ($\text{SPPS}$) and purified using preparative High-Performance Liquid Chromatography ($\text{HPLC}$) to ensure complete removal of deletion sequences and residual organic solvents.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols

Achieving reproducible, publication-grade results when working with AOD-9604 2mg (10 vials/kit) requires strict adherence to standardized laboratory preparation and climate-controlled storage protocols.

Perform all reconstitution procedures inside a certified Class II Biosafety Cabinet:

1. Temperature Equilibration: Allow the frozen AOD-9604 2mg (10 vials/kit) vial to adjust to ambient room temperature prior to solvent introduction to eliminate internal moisture condensation.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol swab. Allow the surface to dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the required volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Phosphate-Buffered Saline (PBS). Direct the liquid stream against the inner glass wall so it trickles slowly over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully hydrate the powder cake for 2 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until clear. Never vortex or shake vigorously, as high-shear agitation can shear peptide bonds and induce protein foaming.

5. Micro-Aliquot Strategy: For multi-week testing protocols, divide reconstituted liquid into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of AOD-9604 2mg (10 vials/kit) undergoes third-party analytical testing. High-Performance Liquid Chromatography (HPLC) chromatograms confirm component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: AOD-9604 2mg (10 vials/kit) is produced, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. AOD-9604 2mg (10 vials/kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.